Related Guidance Notes
GNES 13: The Employer Branding Emergency
GNES 12: Recruitment – Is it still about Cultural Fit?
GNES 11: Importance of Autonomy
GNES 10: Employee Wellness Within a Hybrid Working Model
GNES 9: Reinvention during and after COVID- will company culture stand the test of time?
GNES 8: The Importance of Learning Agility
GNES 7: The Good And Bad of Video Interviewing
GNES 6: The importance of direct approach (in executive search)
GNES 5: Creating a company culture that attracts and retains talent during and post-global pandemic
GNES 4: Attracting the right talent in the times of coronavirus – Job Description as a Talent Magnet
GNES 3: Can/should executive search help improve gender diversity?
GNES 2: Recruit for future-proof profiles
GNL 39: Changes to data exclusivity
GNL37: UK experimental use exemptions
GNL 36: Placing medical devices on the UK market after the end of Brexit transition
GNL 35: What the UK-EU Trade and Cooperation Agreement means for pharma and medical device companies
GNL 25: Data and market exclusivity: additional protections
GNL 21: Licensing manufacturers, wholesale dealers and brokers
GNL 24: Data and market exclusivity: what it is and how long it lasts
GNL 23: IP indemnities in commercial agreements
GNL 20: Paediatric extensions
GNL 19: Pre-clinical, clinical and post-market surveillance
GNL 18: Territorial Licensing
GNL 16: The Execution of Documents – Getting it Right
GNL 15: Keeping Your Confidential Information and Staff Safe From Competition
GNL 14: Medical Devices Regulation – The New Rules
GNL 13: Medical Devices Regulation – The Current Rules
GNL 12: Regulations on Medicine, Advertising and Promotion
GNMA 10: Policy and public affairs for life science companies
GNMA 9: Supranational HTAs
GNMA 8: Market access for medtech, diagnostics and digital technologies in the UK
GNMA 7: Impact of Brexit on the regulatory approval process for medicines in the UK
GNMA 6: Impact of conditional approval and approval under exceptional circumstances on national pricing and reimbursement
GNMA 5: Learning from previous NICE consultations
GNMA 4: Cell and Gene Therapies – innovative contracting trends in Europe
GNMA 3: How can early access schemes support accelerated patient access in Europe?
GNMA 2: Top five reasons why products fail to achieve a positive NICE recommendation
GNMA 1: Improving access to orphan medicines
GNT 72: Tax treatment of interest on convertible loans
GNT 71: Corporate Interest Restriction (CIR)
GNT 70: Working from Home (in the UK and abroad) – Common Tax Concerns
GNT 69: Making Tax Digital for Corporation Tax
GNT 68: Making Tax Digital for VAT
GNT 67: Non-resident directors
GNT 65: A tax overview of share schemes and other equity incentives
GNT 64: Off payroll workers : IR35 for the private sector from April 2021
GNT 59: Corporation Tax Deductions for Employee Share Schemes
GNT 58: Corporate Criminal Offence – As Applied to Life Sciences
GNT 54: PAYE Settlement Agreements (PSAs)
GNT 34: Termination Payments
GNT 23: Permanent Establishments
GNT 13: Expansion into New Territories
GNT 11: Transfer Pricing Essentials
GNT 42: Corporation Tax Loss Relief Reform
GNT 38: Bioscience Explained to Support Tax Returns
GNT 29: Tax Model
GNT 17: Compliance Essentials
GNT 6: Tax Framework and Strategy
GNT 47: Patent Box R&D Fraction – As Applied to Life Sciences
